文献速递系统性红斑狼疮

羟氯喹在狼疮妊娠中的应用与子痫前期风险

Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia.
PubMed 文献 · Arthritis Rheumatol · 2024-02-19

本研究基于2007—2016年商业保险数据库,纳入1,020例系统性红斑狼疮(SLE)患者的1,068次单胎活产妊娠,以孕前3个月至孕早期羟氯喹(HCQ)处方配药为暴露代理,采用改良泊松回归并按产次分层分析。结果显示,初产妇RR 1.26(95%CI 0.82-1.93)、经产妇RR 1.20(95%CI 0.80-1.70),倾向性评分校正后初产妇RR 1.09(95%CI 0.68-1.76)、经产妇RR 1.01(95%CI 0.66-1.53),均未观察到HCQ与子痫前期风险降低的统计学关联。

要点

  • 在1,068次单胎活产妊娠中,约15%被诊断为子痫前期。
  • 52%的妊娠中患者有至少一次HCQ配药记录。
  • 初产妇与经产妇中HCQ与子痫前期均无统计学关联。

核心结论

  • 基于大型保险数据库,未观察到孕期HCQ治疗与子痫前期风险降低相关,但不能排除残余和未测量混杂及错分。
  • 作者提出需利用大型人群数据及前瞻性收集进一步研究HCQ如何影响SLE孕妇的子痫前期风险及高血压疾病高风险人群。

研究设计与样本

  • 研究纳入2007—2016年1,020例商业保险SLE患者的1,068次单胎活产妊娠。
  • HCQ暴露定义为孕前3个月至孕早期(前三个月)有处方配药记录,以配药记录作为服用HCQ的代理指标。
  • 采用改良泊松回归估计风险比(RR)及95%置信区间(CI),按产次分层,并用倾向性评分控制混杂因素及进行分层分析评估效应修饰。

主要发现

  • 约15%的妊娠患者被诊断为子痫前期。
  • 52%的妊娠中患者有至少一次HCQ配药记录。
  • 暴露于HCQ的妊娠患者合并症更多、SLE活动度更高且接受硫唑嘌呤治疗更多。
  • 初产妇中HCQ与子痫前期无统计学关联(RR 1.26 [95%CI 0.82-1.93]),经产妇中亦无统计学关联(RR 1.20 [95%CI 0.80-1.70])。
  • 进一步控制混杂后RR趋近于无效值:初产妇倾向性评分校正RR 1.09(95%CI 0.68-1.76),经产妇倾向性评分校正RR 1.01(95%CI 0.66-1.53)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出不能排除残余和未测量的混杂。
  • 原文指出不能排除错分。
  • 原文结论提出需利用大型人群数据及前瞻性收集进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years, and hydroxychloroquine (HCQ) is the standard first-line treatment. Preeclampsia complicates up to one-third of pregnancies in lupus patients, although reports vary by parity and multifetal gestation. We investigated whether taking HCQ early in pregnancy may reduce the risk of preeclampsia. METHODS: We studied 1,068 live birth singleton pregnancies among 1,020 privately insured patients with SLE (2007-2016). HCQ treatment was defined as three months preconception through the first trimester, and prescription fills were a proxy for taking HCQ. Modified Poisson regression estimated risk ratios (RRs) and 95% confidence intervals (CIs), stratified by parity. Propensity scores accounted for confounders, and stratified analyses examined effect modification. RESULTS: Approximately 15% of pregnant patients were diagnosed with preeclampsia. In 52% of pregnancies, patients had one or more HCQ fills. Pregnant patients exposed to HCQ had more comorbidities, SLE activity, and azathioprine treatment. We found no evidence of a statistical association between HCQ and preeclampsia among nulliparous (RR 1.26 [95% CI 0.82-1.93]) and multiparous pregnancies (RR 1.20 [95% CI 0.80-1.70]). Additional controls for confounding decreased the RRs toward the null (nulliparous pregnancy, propensity score-adjusted [PS-adj] RR 1.09 [95% CI 0.68-1.76]; multiparous pregnancy, PS-adj RR 1.01 [95% CI 0.66-1.53]). CONCLUSION: Using a large insurance-based database, we did not observe a decreased risk of preeclampsia associated with HCQ treatment in pregnancy, although we cannot rule out residual and unmeasured confounding and misclassification. Further studies leveraging large population-based data and prospective collection could characterize how HCQ influences preeclampsia risk in pregnant patients with SLE and among persons at greater risk of hypertensive disorders of pregnancy.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rector A, Marić I, Chaichian Y, et al. Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia. Arthritis Rheumatol. 2024. PMID: 38272838. doi:10.1002/art.42793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。